PTPN22 Silencing in Human Acute T-Cell Leukemia Cell Line (Jurkat Cell) and its Effect on the Expression of miR-181a and miR-181b

Elham Baghbani ¹, Vahid Khaze ¹, Sanam Sadreddini ¹, Ahad Mokhtarzadeh ¹, Behzad Mansoori ¹, Ali Mohammadi ¹, Vida Vatankhahan ¹, Parisa Toosi ¹, Behzad Baradaran ¹ *

Cited by CrossRef: 4

1- Kou Z, Mao M, Liu H, Wang X, Wang Z, Gu Z, Lang T, Nie Y, Wang Y, Huang Q, An L, Zhang X, Fu L, Li Y. Card11 Is A Novel Target of Mir-181B That Is Upregulated in Chronic Lymphocytic Leukemia. Biomark Med. 2021;15(9):623 [Crossref]

2- Kakavandi S, Hajikhani B, Azizi P, Aziziyan F, Nabi-Afjadi M, Farani M, Zalpoor H, Azarian M, Saadi M, Gharesi-Fard B, Terpos E, Zare I, Motamedifar M. COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches. Cell Commun Signal. 2024;22(1) [Crossref]

3- Shen D, Hong Y, Feng Z, Chen X, Cai Y, Peng Q, Tu J. Development of dynamical network biomarkers for regulation in Epstein-Barr virus positive peripheral T cell lymphoma unspecified type. Front Genet. 2022;13 [Crossref]

4- Sulyman A, Yusuf T, Aribisala J, Ibrahim K, Ajani E, Ajiboye A, Sabiu S, Singh K. Quercetin as a Modulator of PTPN22 Phosphomonoesterase Activity: A Biochemical and Computational Evaluation. CIMB. 2024;46(10):11156 [Crossref]

5- Jadideslam G, Ansarin K, Sakhinia E, Babaloo Z, Abhari A, Ghahremanzadeh K, Khalili M, Radmehr R, Kabbazi A. Diagnostic biomarker and therapeutic target applications of miR‐326 in cancers: A systematic review. Journal Cellular Physiology. 2019;234(12):21560 [Crossref]